Solid Biosciences (SLDB) Gains from Sales and Divestitures (2018 - 2026)
Quarterly results put Gains from Sales and Divestitures at $518546.0 for Q1 2026, up 109.12% from a year ago — trailing twelve months through Mar 2026 was $518546.0 (up 109.12% YoY), and the annual figure for FY2025 was $434314.0, up 29.27%.
Solid Biosciences has reported Gains from Sales and Divestitures over the past 8 years, most recently at $518546.0 for Q1 2026.
- Gains from Sales and Divestitures reached $518546.0 in Q1 2026 per SLDB's latest filing, up from $434314.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $518546.0 in Q1 2026 and bottomed at $183951.0 in Q4 2023.
- Median Gains from Sales and Divestitures over the past 4 years was $280159.0 (2025), compared with a mean of $310251.0.
- The largest annual shift saw Gains from Sales and Divestitures grew 21.53% in 2025 before it skyrocketed 109.12% in 2026.
- Over 4 years, Gains from Sales and Divestitures stood at $183951.0 in 2023, then surged by 82.65% to $335981.0 in 2024, then rose by 29.27% to $434314.0 in 2025, then grew by 19.39% to $518546.0 in 2026.
- Business Quant data shows Gains from Sales and Divestitures for SLDB at $518546.0 in Q1 2026, $434314.0 in Q4 2025, and $323487.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 518,546.00 |
| Mar 31, 2026 | 518,546.00 |
| Dec 31, 2025 | 434,314.00 |
| Dec 31, 2025 | 434,314.00 |
| Sep 30, 2025 | 323,487.00 |
| Sep 30, 2025 | 323,487.00 |
| Jun 30, 2025 | 280,159.00 |
| Jun 30, 2025 | 280,159.00 |
| Mar 31, 2025 | 247,970.00 |
| Mar 31, 2025 | 247,970.00 |
| Dec 31, 2024 | 335,981.00 |
| Dec 31, 2024 | 335,981.00 |
| Sep 30, 2024 | 237,315.00 |
| Sep 30, 2024 | 237,315.00 |
| Jun 30, 2024 | 230,536.00 |
| Jun 30, 2024 | 230,536.00 |
| Dec 31, 2023 | 183,951.00 |
| Dec 31, 2023 | 183,951.00 |
| Dec 31, 2021 | 419,193.00 |
| Dec 31, 2021 | 419,193.00 |
| Dec 31, 2020 | 407,700.00 |
| Dec 31, 2020 | 407,700.00 |
| Dec 31, 2019 | 338,198.00 |
| Dec 31, 2019 | 338,198.00 |
| Dec 31, 2018 | 334,144.00 |
| Dec 31, 2018 | 334,144.00 |
| Sep 30, 2018 | 243,881.00 |
| Sep 30, 2018 | 243,881.00 |
| Jun 30, 2018 | 138,974.00 |
| Jun 30, 2018 | 138,974.00 |
| Mar 31, 2018 | 56,655.00 |
| Mar 31, 2018 | 56,655.00 |